Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results